

=> d his

(FILE 'HOME' ENTERED AT 16:34:02 ON 12 DEC 2011)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS' ENTERED AT 16:34:14 ON 12 DEC 2011

L2 2739 S HU? (L) (CYTOMEGALOVIRUS OR CMV) (L) ENHANCER
 L3 1965 S MOUSE (L) BETA (L) ACTIN (L) PROMOTER
 L4 169 S L2 (L) L3
 L5 62 DUP REM L4 (107 DUPLICATES REMOVED)
 L6 38 S L5 AND PY<=2004
 L7 38 FOCUS L6 1-
 L8 0 S L7 AND (MOUSE BETA?)
 L9 2 S L7 AND (MOUSE (2W) BETA?)
 L10 9 S MOUSE B-ACTIN PROMOTER
 L11 0 S L10 AND L2
 L12 4 DUP REM L10 (5 DUPLICATES REMOVED)

=> d ti so au ab pi l12 l-4

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN

TI Hybrid mouse .beta.-actin promoter with cytomegalovirus
 enhancer/woodchuck hepatitis virus posttranscriptional regulatory element
 and uses

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

IN Tsunoda, Hiroyuki; Habu, Kiyoshi

AB Hybrid promoters prepared by combining various gene promoters and enhancers,
 and use in production of desired proteins, omnipotent cells, or transgenic
 animals, are disclosed. It was found that a hybrid promoter comprising a
 combination of CMV enhancer with a mammalian β -actin promoter or a
 combination of the Woodchuck Hepatitis Virus posttranscriptional
 regulatory element (WPRES) with a mammalian β -actin promoter, is
 superior in activity to the existing promoters. It was also found that
 the activity of this β -actin promoter is enhanced by the simultaneous
 expression of an oncogene product Ras which is a transactivator. In this
 study the authors have enhanced the efficacy of DNA vaccines by adopting
 strategies that increase gene expression. The authors generated
 influenza-hemagglutinin (HA)-encoding DNA vaccines that contain the hybrid
 CMV enhancer/chicken β -actin (CAG) promoter and/or the
 mRNA-stabilizing post-transcriptional regulatory element from the
 woodchuck hepatitis virus (WPRES). DNA vaccines consisting of both CAG and
 WPRES elements (pCAG-HA-WPRES) induced the highest level of protective
 immunity, such that immunization with 10-fold lower DNA doses prevented
 death in 100% of the mice upon lethal viral challenge, whereas all mice
 immunized with the conventional pCMV-HA vaccine succumbed to influenza
 infection.

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------|---|----------|-----------------|----------|
| PI WO 2005054467 | A1 | 20050616 | WO 2004-JP18006 | 20041203 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, | | | |

STN Seach HistoryPrint selected from Online session

| | | |
|----------------|---|---------------------------|
| | TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, | |
| | AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, | |
| | EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, | |
| | RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, | |
| | HR, NE, SN, TD, TG | |
| AU 2004295590 | A1 20050616 | AU 2004-295590 20041203 |
| AU 2004295590 | B2 20100429 | |
| CA 2548185 | A1 20050616 | CA 2004-2548185 20041203 |
| EP 1707629 | A1 20061004 | EP 2004-819918 20041203 |
| EP 1707629 | B1 20110608 | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | |
| | IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | |
| CN 1914320 | A 20070214 | CN 2004-80041348 20041203 |
| SG 164436 | A1 20100929 | SG 2010-5748 20041203 |
| EP 2270152 | A1 20110105 | EP 2010-10437 20041203 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, | |
| | IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, | |
| | HR, LV, MK, YU | |
| AT 512232 | T 20110615 | AT 2004-819918 20041203 |
| KR 2006123413 | A 20061201 | KR 2006-7013218 20060630 |
| IN 2006DN03783 | A 20070713 | IN 2006-DN3783 20060630 |
| IN 235423 | A1 20090731 | |
| US 20080250514 | A1 20081009 | US 2007-581183 20070518 |
| IN 2009DN02296 | A 20090612 | IN 2009-DN2296 20090408 |